New antimicrobial agents are urgently needed, especially to eliminate multidrug resistant Gram‐ negative bacteria that stand for most antibiotic‐resistant threats. In the following study, we present superior properties of an engineered antimicrobial peptide, OMN6, a 40‐amino acid cyclic peptide based on Cecropin A . . . READ ARTICLE PUBLISHED MARCH 23, 2021
Omnix Medical Secures $25 Million in Series C Funding Co-Led by Harel Insurance & Finance and the EIC Fund
— Existing and new investors joining forces to support the accelerated development of Omnix´s novel, first-in-class antimicrobials pipeline — Funding underlines urgent global need for
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).